ETFs MorphoSys Xetra

Equities

MOR

DE0006632003

Market Closed - Xetra 11:36:08 2024-08-02 EDT 5-day change 1st Jan Change
67.25 EUR -0.66% Intraday chart for MorphoSys -.--% -.--%

ETFs positioned on MorphoSys

Name Weight AuM 1st Jan change
2.44% 0 M€ -.--% -
-0% 27 M€ 0.00% -
Logo MorphoSys
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
464
Sector
-
More about the company